1-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-3-yl)-1H-imidazole

Catalog No. :
ACBPZH564
CAS No. :
2223032-27-5
Molecular Formula :
C13H17BN2O2S
Molecular Weight :
276.17

IUPAC Name:1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-3-yl)-1H-imidazole

1-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-3-yl)-1H-imidazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-3-yl)-1H-imidazole
IUPAC Name1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-3-yl)-1H-imidazole
Molecular FormulaC13H17BN2O2S
Molecular Weight276.17
SMILESCC1(C)C(C)(C)OB(C2=CC(N3C=CN=C3)=CS2)O1
InChI KeyRONSWOAVXSVSLJ-UHFFFAOYSA-N
Synonym4-(Imidazol-1-yl)thiophene-2-boronic acid pinacol ester;1H-Imidazole, 1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-thienyl]-
CAS No.2223032-27-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACBPZH564 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACBPZH564 route product structure diagram
    ACBPZH5642223032-27-5
Inquiry

2. ACBPZH564 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACDLYM406 route compound structure diagram
    ACDLYM4065587-42-8 In Stock
  4. Then
  5. ACBPZH564 route product structure diagram
    ACBPZH5642223032-27-5
Inquiry

Comments (0)